Bristol-Myers Squibb Company (BMY) Shares Sold by Capital Asset Advisory Services LLC
Capital Asset Advisory Services LLC decreased its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 6.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,521 shares of the biopharmaceutical company’s stock after selling 710 shares during the quarter. Capital Asset Advisory Services LLC’s holdings in Bristol-Myers Squibb were worth $587,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Blue Chip Partners Inc. lifted its holdings in Bristol-Myers Squibb by 0.8% during the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 17 shares in the last quarter. Keel Point LLC raised its holdings in shares of Bristol-Myers Squibb by 0.3% in the 1st quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 18 shares in the last quarter. Staley Capital Advisers Inc. raised its holdings in shares of Bristol-Myers Squibb by 0.3% in the 1st quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after purchasing an additional 24 shares in the last quarter. Shayne & CO. LLC raised its holdings in shares of Bristol-Myers Squibb by 0.7% in the 1st quarter. Shayne & CO. LLC now owns 4,017 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 27 shares in the last quarter. Finally, Founders Capital Management LLC raised its holdings in shares of Bristol-Myers Squibb by 0.7% in the 1st quarter. Founders Capital Management LLC now owns 4,097 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 29 shares in the last quarter. Institutional investors own 68.88% of the company’s stock.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Theodore R. Samuels II acquired 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by company insiders.
Several equities research analysts have recently commented on the stock. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. Vetr lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price target for the company. in a report on Tuesday, August 22nd. Deutsche Bank AG set a $55.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, July 17th. Credit Suisse Group set a $58.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Wednesday, August 16th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $62.66.
Bristol-Myers Squibb Company (BMY) traded up 0.78% during mid-day trading on Monday, reaching $62.97. 2,821,908 shares of the company’s stock traded hands. The stock’s 50 day moving average is $58.56 and its 200-day moving average is $55.95. The stock has a market capitalization of $103.27 billion, a PE ratio of 23.00 and a beta of 1.18. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $63.47.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter last year, the company earned $0.69 earnings per share. The firm’s revenue was up 5.6% compared to the same quarter last year. On average, equities analysts anticipate that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be issued a dividend of $0.39 per share. The ex-dividend date is Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.50%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/18/bristol-myers-squibb-company-bmy-shares-sold-by-capital-asset-advisory-services-llc.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.